Universal Health warns of possible impact to annual results from Medicaid changes; Q3 revenue slightly beats

By Reuters News


Overview

  • US hospital operator's Q3 revenue rose 5.3%, slightly beating analyst expectations

  • Q3 adjusted EPS fell year-over-year; no analyst consensus for EPS

  • Company repurchased 1.35 mln shares for $242.1 mln in Q3


Outlook

  • Company warns changes to Medicaid programs could materially impact 2026 results

  • Company expects new Medicaid eligibility rules to reduce revenue and increase uncompensated care

  • Company says higher interest rates could further impact future results and cash flow


Result Drivers

  • HIGHER ACUTE CARE VOLUMES - Co said increased adjusted admissions and patient days at acute care hospitals drove revenue growth

  • BEHAVIORAL HEALTH GROWTH - Co said higher admissions and patient days at behavioral health facilities contributed to revenue rise

  • LOWER ACUTE CARE REVENUE PER PATIENT - Co said net revenue per adjusted admission and patient day fell at acute care hospitals


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$4.73 bln

$4.71 bln (16 Analysts)

Q3 EPS

$5.22

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 14 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Universal Health Services, Inc. is $195.50, about 5.3% above its October 26 closing price of $185.71

  • The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 6 three months ago


Reuters Recommended Reads

  • Oct 27 - HCA signals flat 2027 earnings as Medicaid payments drop; shares slide

  • Oct 27 - Centene Q3 revenue tops estimates on Medicare growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.